O	0	3	The	The	DT	B-NP
O	4	8	EGFR	EGFR	NN	I-NP
O	8	9	-	-	HYPH	B-NP
O	9	15	GEP100	GEP100	NN	I-NP
O	15	16	-	-	HYPH	B-NP
O	16	20	Arf6	Arf6	NN	I-NP
O	20	21	-	-	HYPH	I-NP
O	21	26	AMAP1	AMAP1	NN	I-NP
O	27	36	signaling	signaling	NN	I-NP
O	37	44	pathway	pathway	NN	I-NP
O	45	53	specific	specific	JJ	B-ADJP
O	54	56	to	to	TO	B-PP
B-Cancer	57	63	breast	breast	NN	B-NP
I-Cancer	64	70	cancer	cancer	NN	I-NP
O	71	79	invasion	invasion	NN	I-NP
O	80	83	and	and	CC	I-NP
O	84	94	metastasis	metastasis	NN	I-NP
O	94	95	.	.	.	O

B-Cancer	97	103	Tumors	Tumor	NNS	B-NP
O	104	107	are	be	VBP	B-VP
B-Tissue	108	114	tissue	tissue	NN	B-NP
O	114	115	-	-	HYPH	B-NP
O	115	123	specific	specific	JJ	I-NP
O	124	132	diseases	disease	NNS	I-NP
O	132	133	,	,	,	O
O	134	137	and	and	CC	O
O	138	143	their	their	PRP$	B-NP
O	144	154	mechanisms	mechanism	NNS	I-NP
O	155	157	of	of	IN	B-PP
O	158	166	invasion	invasion	NN	B-NP
O	167	170	and	and	CC	I-NP
O	171	181	metastasis	metastasis	NN	I-NP
O	182	185	are	be	VBP	B-VP
O	186	192	highly	highly	RB	B-ADJP
O	193	200	diverse	diverse	JJ	I-ADJP
O	200	201	.	.	.	O

O	202	204	In	In	IN	B-PP
B-Cancer	205	211	breast	breast	NN	B-NP
I-Cancer	212	218	cancer	cancer	NN	I-NP
O	218	219	,	,	,	O
O	220	230	biomarkers	biomarker	NNS	B-NP
O	231	235	that	that	WDT	B-NP
O	236	248	specifically	specifically	RB	B-ADVP
O	249	258	correlate	correlate	VBP	B-VP
O	259	263	with	with	IN	B-PP
O	264	267	the	the	DT	B-NP
O	268	276	invasive	invasive	JJ	I-NP
O	277	287	phenotypes	phenotype	NNS	I-NP
O	288	292	have	have	VBP	B-VP
O	293	296	not	not	RB	I-VP
O	297	301	been	be	VBN	I-VP
O	302	309	clearly	clearly	RB	I-VP
O	310	320	identified	identify	VBN	I-VP
O	320	321	.	.	.	O

O	322	323	A	A	DT	B-NP
O	324	329	small	small	JJ	I-NP
O	330	336	GTPase	GTPase	NN	I-NP
O	337	341	Arf6	Arf6	NN	I-NP
O	342	351	primarily	primarily	RB	B-ADVP
O	352	361	regulates	regulate	VBZ	B-VP
O	362	371	recycling	recycling	NN	B-NP
O	372	374	of	of	IN	B-PP
B-Cellular_component	375	381	plasma	plasma	NN	B-NP
I-Cellular_component	382	390	membrane	membrane	NN	I-NP
I-Cellular_component	391	401	components	component	NNS	I-NP
O	401	402	.	.	.	O

O	403	405	We	We	PRP	B-NP
O	406	410	have	have	VBP	B-VP
O	411	416	shown	show	VBN	I-VP
O	417	421	that	that	IN	B-SBAR
O	422	426	Arf6	Arf6	NN	B-NP
O	427	430	and	and	CC	O
O	431	434	its	its	PRP$	B-NP
O	435	443	effector	effector	NN	I-NP
O	444	449	AMAP1	AMAP1	NN	I-NP
O	450	451	(	(	(	O
O	451	456	DDEF1	DDEF1	NN	B-NP
O	456	457	,	,	,	O
O	458	462	DEF1	DEF1	NN	B-NP
O	462	463	,	,	,	O
O	464	469	ASAP1	ASAP1	NN	B-NP
O	470	473	and	and	CC	O
O	474	483	centaurin	centaurin	NN	B-NP
O	484	489	beta4	beta4	NN	I-NP
O	489	490	)	)	)	O
O	491	494	are	be	VBP	B-VP
O	495	505	abnormally	abnormally	RB	I-VP
O	506	519	overexpressed	overexpresse	VBN	I-VP
O	520	522	in	in	IN	B-PP
O	523	527	some	some	DT	B-NP
B-Cancer	528	534	breast	breast	NN	I-NP
I-Cancer	535	542	cancers	cancer	NNS	I-NP
O	543	546	and	and	CC	O
O	547	551	used	use	VBN	B-VP
O	552	555	for	for	IN	B-PP
O	556	561	their	their	PRP$	B-NP
O	562	570	invasion	invasion	NN	I-NP
O	571	574	and	and	CC	I-NP
O	575	585	metastasis	metastasis	NN	I-NP
O	585	586	.	.	.	O

O	587	601	Overexpression	Overexpression	NN	B-NP
O	602	604	of	of	IN	B-PP
O	605	610	these	these	DT	B-NP
O	611	619	proteins	protein	NNS	I-NP
O	620	622	is	be	VBZ	B-VP
O	623	634	independent	independent	JJ	B-ADJP
O	635	637	of	of	IN	B-PP
O	638	641	the	the	DT	B-NP
O	642	657	transcriptional	transcriptional	JJ	I-NP
O	658	670	upregulation	upregulation	NN	I-NP
O	671	673	of	of	IN	B-PP
O	674	679	their	their	PRP$	B-NP
O	680	685	genes	gene	NNS	I-NP
O	685	686	,	,	,	O
O	687	690	and	and	CC	O
O	691	697	occurs	occur	VBZ	B-VP
O	698	702	only	only	RB	B-ADVP
O	703	705	in	in	IN	B-PP
O	706	712	highly	highly	RB	B-NP
B-Cell	713	722	malignant	malignant	JJ	I-NP
I-Cell	723	729	breast	breast	NN	I-NP
I-Cell	730	736	cancer	cancer	NN	I-NP
I-Cell	737	742	cells	cell	NNS	I-NP
O	742	743	.	.	.	O

O	744	746	We	We	PRP	B-NP
O	747	755	recently	recently	RB	B-ADVP
O	756	766	identified	identify	VBD	B-VP
O	767	773	GEP100	GEP100	NN	B-NP
O	774	775	(	(	(	O
O	775	780	BRAG2	BRAG2	NN	B-NP
O	780	781	)	)	)	O
O	782	784	to	to	TO	B-VP
O	785	787	be	be	VB	I-VP
O	788	799	responsible	responsible	JJ	B-ADJP
O	800	803	for	for	IN	B-PP
O	804	807	the	the	DT	B-NP
O	808	812	Arf6	Arf6	NN	I-NP
O	813	823	activation	activation	NN	I-NP
O	824	826	to	to	TO	B-VP
O	827	833	induce	induce	VB	I-VP
O	834	842	invasion	invasion	NN	B-NP
O	843	846	and	and	CC	I-NP
O	847	857	metastasis	metastasis	NN	I-NP
O	857	858	,	,	,	O
O	859	861	by	by	IN	B-PP
O	862	870	directly	directly	RB	B-VP
O	871	878	binding	bind	VBG	I-VP
O	879	881	to	to	TO	B-PP
O	882	888	ligand	ligand	NN	B-NP
O	888	889	-	-	HYPH	O
O	889	898	activated	activate	VBN	B-VP
O	899	908	epidermal	epidermal	JJ	B-NP
O	909	915	growth	growth	NN	I-NP
O	916	922	factor	factor	NN	I-NP
O	923	931	receptor	receptor	NN	I-NP
O	932	933	(	(	(	O
O	933	937	EGFR	EGFR	NN	B-NP
O	937	938	)	)	)	O
O	938	939	.	.	.	O

O	940	941	A	A	DT	B-NP
O	942	948	series	series	NN	I-NP
O	949	951	of	of	IN	B-PP
O	952	955	our	our	PRP$	B-NP
O	956	963	studies	study	NNS	I-NP
O	964	972	revealed	reveal	VBD	B-VP
O	973	977	that	that	IN	B-SBAR
O	978	981	for	for	IN	B-PP
O	982	992	activation	activation	NN	B-NP
O	993	995	of	of	IN	B-PP
O	996	999	the	the	DT	B-NP
O	1000	1008	invasion	invasion	NN	I-NP
O	1009	1016	pathway	pathway	NN	I-NP
O	1017	1019	of	of	IN	B-PP
O	1020	1024	EGFR	EGFR	NN	B-NP
O	1024	1025	,	,	,	O
O	1026	1028	it	it	PRP	B-NP
O	1029	1031	is	be	VBZ	B-VP
O	1032	1044	prerequisite	prerequisite	JJ	B-ADJP
O	1045	1049	that	that	IN	B-SBAR
O	1050	1054	Arf6	Arf6	NN	B-NP
O	1055	1058	and	and	CC	I-NP
O	1059	1064	AMAP1	AMAP1	NN	I-NP
O	1065	1069	both	both	DT	B-NP
O	1070	1073	are	be	VBP	B-VP
O	1074	1080	highly	highly	RB	I-VP
O	1081	1094	overexpressed	overexpresse	VBN	I-VP
O	1094	1095	,	,	,	O
O	1096	1099	and	and	CC	O
O	1100	1104	that	that	IN	B-SBAR
O	1105	1109	EGFR	EGFR	NN	B-NP
O	1110	1112	is	be	VBZ	B-VP
O	1113	1122	activated	activate	VBN	I-VP
O	1123	1125	by	by	IN	B-PP
O	1126	1133	ligands	ligand	NNS	B-NP
O	1133	1134	.	.	.	O

O	1135	1147	Pathological	Pathological	JJ	B-NP
O	1148	1156	analyses	analysis	NNS	I-NP
O	1157	1165	indicate	indicate	VBP	B-VP
O	1166	1170	that	that	IN	B-SBAR
O	1171	1172	a	a	DT	B-NP
O	1173	1184	significant	significant	JJ	I-NP
O	1185	1190	large	large	JJ	I-NP
O	1191	1201	population	population	NN	I-NP
O	1202	1204	of	of	IN	B-PP
O	1205	1210	human	human	JJ	B-NP
B-Cancer	1211	1217	ductal	ductal	JJ	I-NP
I-Cancer	1218	1225	cancers	cancer	NNS	I-NP
O	1226	1229	may	may	MD	B-VP
O	1230	1237	utilize	utilize	VB	I-VP
O	1238	1241	the	the	DT	B-NP
O	1242	1246	EGFR	EGFR	NN	I-NP
O	1246	1247	-	-	HYPH	B-NP
O	1247	1253	GEP100	GEP100	NN	I-NP
O	1253	1254	-	-	HYPH	B-NP
O	1254	1258	Arf6	Arf6	NN	I-NP
O	1258	1259	-	-	HYPH	I-NP
O	1259	1264	AMAP1	AMAP1	NN	I-NP
O	1265	1272	pathway	pathway	NN	I-NP
O	1273	1276	for	for	IN	B-PP
O	1277	1282	their	their	PRP$	B-NP
O	1283	1293	malignancy	malignancy	NN	I-NP
O	1293	1294	.	.	.	O

O	1295	1312	Microenvironments	Microenvironment	NNS	B-NP
O	1313	1317	have	have	VBP	B-VP
O	1318	1322	been	be	VBN	I-VP
O	1323	1329	highly	highly	RB	I-VP
O	1330	1340	implicated	implicate	VBN	I-VP
O	1341	1343	in	in	IN	B-PP
O	1344	1347	the	the	DT	B-NP
O	1348	1358	malignancy	malignancy	NN	I-NP
O	1359	1361	of	of	IN	B-PP
B-Cancer	1362	1369	mammary	mammary	JJ	B-NP
I-Cancer	1370	1376	tumors	tumor	NNS	I-NP
O	1376	1377	.	.	.	O

O	1378	1381	Our	Our	PRP$	B-NP
O	1382	1389	results	result	NNS	I-NP
O	1390	1396	reveal	reveal	VBP	B-VP
O	1397	1399	an	an	DT	B-NP
O	1400	1406	aspect	aspect	NN	I-NP
O	1407	1409	of	of	IN	B-PP
O	1410	1413	the	the	DT	B-NP
O	1414	1421	precise	precise	JJ	I-NP
O	1422	1431	molecular	molecular	JJ	I-NP
O	1432	1442	mechanisms	mechanism	NNS	I-NP
O	1443	1445	of	of	IN	B-PP
O	1446	1450	some	some	DT	B-NP
B-Cancer	1451	1457	breast	breast	NN	I-NP
I-Cancer	1458	1465	cancers	cancer	NNS	I-NP
O	1465	1466	,	,	,	O
O	1467	1469	in	in	IN	B-PP
O	1470	1475	which	which	WDT	B-NP
O	1476	1480	full	full	JJ	B-NP
O	1481	1493	invasiveness	invasiveness	NN	I-NP
O	1494	1496	is	be	VBZ	B-VP
O	1497	1500	not	not	RB	I-VP
O	1501	1509	acquired	acquire	VBN	I-VP
O	1510	1514	just	just	RB	B-ADVP
O	1515	1517	by	by	IN	B-PP
B-Immaterial_anatomical_entity	1518	1531	intracellular	intracellular	JJ	B-NP
O	1532	1543	alterations	alteration	NNS	I-NP
O	1544	1546	of	of	IN	B-PP
B-Cell	1547	1553	cancer	cancer	NN	B-NP
I-Cell	1554	1559	cells	cell	NNS	I-NP
O	1559	1560	,	,	,	O
O	1561	1564	but	but	CC	O
B-Immaterial_anatomical_entity	1565	1578	extracellular	extracellular	JJ	B-NP
O	1579	1586	factors	factor	NNS	I-NP
O	1587	1591	from	from	IN	B-PP
O	1592	1609	microenvironments	microenvironment	NNS	B-NP
O	1610	1613	may	may	MD	B-VP
O	1614	1618	also	also	RB	I-VP
O	1619	1621	be	be	VB	I-VP
O	1622	1631	necessary	necessary	JJ	B-ADJP
O	1631	1632	.	.	.	O

O	1633	1641	Possible	Possible	JJ	B-NP
O	1642	1653	translation	translation	NN	I-NP
O	1654	1656	of	of	IN	B-PP
O	1657	1660	our	our	PRP$	B-NP
O	1661	1670	knowledge	knowledge	NN	I-NP
O	1671	1673	to	to	TO	B-PP
B-Cancer	1674	1680	cancer	cancer	NN	B-NP
O	1681	1693	therapeutics	therapeutic	NNS	I-NP
O	1694	1698	will	will	MD	B-VP
O	1699	1703	also	also	RB	I-VP
O	1704	1706	be	be	VB	I-VP
O	1707	1716	discussed	discuss	VBN	I-VP
O	1716	1717	.	.	.	O

